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Charlottesville . Virginia
Myocardial contrast echocardiography is a new diag-
nostic cardiovascular imaging technique capable of de-
fining perfusion zones of coronary vessels in vivo; ulti-
mately, it may be used to measure absolute regional
myocardial blood flow. However, before it can be used
in humans, its safety must be clearly established. Ac-
cordingly, the electrocardiographic and hemodynamic
effects of intracoronary injections of 2 cc of sonicated
Renografin-76 were compared with 5 to 10 cc of non-
sonicated Renografin-76 in 10subjects with normal coro-
nary arteries. Two cubic centimeters of sonicated Ren-
ografin provides optimal myocardial opacification during
echocardiography, while 5 to 10 cc of Renografin is re-
quired for an adequate coronary arteriogram.
During coronary arteriography, heart rate decreased
while PR and QT intervals and QRS duration increased
as compared with baseline and myocardial contrast
echocardiography (p < 0.01). Similarly, the decrease in
Myocardial contrast echocardiography is a new diagnostic
cardiovascular imaging technique capable of defining per-
fusion zones of coronary vessels in vivo; ultimately, it may
be used to measure absolute regional myocardial blood flow
(1-6). This technique has also been used to assess serially
changes in total left ventricular "area at risk" during ex-
perimental myocard ial infarction (7) . It therefore has the
potential for defining coronary perfusion beds before and
after coronary angioplasty and determining the physiologic
significance of coronary stenoses and the left ventricular
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aortic pressure and first derivative of left ventricular
pressure (dP/dt) was significantly(p < 0.01) greater dur-
ing routine coronary arteriography than during myo-
cardial contrast echocardiography. Changes in left ven-
tricular end-diastolic or pulmonary capillary wedge
pressure were similar during myocardial contrast echo-
cardiography and coronary angiography. There were no
significant differences in the duration of electrocardio-
graphic and hemodynamic changes between myocardial
contrast echocardiography and coronary arteriography.
It is concluded that intracoronary injection of 2 cc of
sonicated Renografin-Zfi provides optimal myocardial
opacification. It is safe in humans , producing transient
electrocardiographic and hemodynamic alterations that
are less pronounced than those seen during routine coro-
nary angiography.
(J Am Coil CardioL 1986;8:1066-72)
" area at risk" for necrosis during acute myocardial infarc -
tion. However, before its use in human patients, its safety
must be clearly established.
To produce contrast enhancement of the myocardium,
microbubbles of air are produced in the contrast medium
(8). To determine whether these microbubbles produce del-
eterious effects on the myocardium, brain and kidneys, Gil-
lam et al. (9) injected a hand-ag itated Renografin and saline
mixture into the coronary , carotid and renal arteries of dogs
and found no pathologic effects 24 hours later. They doc-
umented definite but transient changes in hemodynamics
and left ventricular wall motion during contrast injections .
In a preliminary report, Lang et al. (10) showed that tran-
sient alterations in left ventricular function during intracor-
onary injection of sonicated contra st agents in dogs are
related to the contrast agents themselves, rather than to the
presence of microbubbles.
Routine coronary arteriography in humans requires in-
jection of an iodinated nonoxygen-carrying contrast agent
into the epicardial coronary arteries . Transient hemody-
namic, metabolic and electrocardiographic changes have
been observed in humans during this procedure, probably
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Figure 1. Contrast -enhanced echocardiograms with intracoronary
injection of sonicated Renografin-76 (2 cc) in a subject with normal
coronary arteries . The Renografin-76 produced optimal myocardial
opacification of the left main coronary artery (LMCA) (left) and
right coronary artery (RCA) (right) perfusion beds in a short-axis
view at the mid-papillary muscle level. LV = left ventricle;
RC = right coronary; RV = right ventricle .
cordings of all seven leads were obtained before , during
and for 5 seconds after injection, a time that roughly cor-
responded to the nadir of the hemodynamic changes. Lead
II was recorded continuously throughout the study .
Echocardiographic recordings. Two-dimensional echo-
cardiographic images were obtained using a phased array
system (Hewlett Packard Corporation , model 77020A ul-
trasound system) with a 2.5 MHz transducer. Images were
recorded on 1/ 2 inch (1.27 ern) videotapes using a commer-
cially available video recorder (Panasonic, model AG-63(0).
All recordings were obtained in the parasternal short-axis
projection at the mid-papillary muscle level with the patient
in the supine position. Recordings were started approxi-
mately 10 seconds before injection of sonicated Renografin-
76 and continued until contrast enhancement was no longer
evident.
Two to three milliliters of sonicated Renografin-76 was
used for each injection during myocardial contrast echo-
cardiography. Our animal data and pilot studies in human s
have demonstrated that this amount provides optimal myo-
cardial opacification . Figure I is an example of such an
injection in one of our patient s, illustrating two short-axis
views after left and right coronary injection of sonicated
contrast agent. During contrast injection , approximately I
cc enters the myocardium; the remainder fills the coronary
catheter dead space . Larger amount s of contrast agent result
in a " blooming" effect on the video screen and cause de-
terioration of images (18). Renografin-76 was sonicated us-
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Study patients. Patients with chest pain and a low pre-
test likelihood of coronary artery disease (17) who were
referred to our institution for cardiac catheterization were
recruited for this study. All such patients gave informed
consent to the protocol approved by the Human Investigation
Committee at the University of Virginia School of Medicine.
Myocardial contrast echocardiography was performed in the
patients in this group who were found to have normal coro-
nary arteries during coronary arteriography. Ten patient s
(three men and seven women) with a mean age of 53 ±
12 years (range 37 to 74) form the basi s of this report .
Symptoms and signs. Occurrence of chest pain, visual
disturbances or neurologic sequelae were monitored during
and for 24 hours after the study.
Hemodynamic measurements. All patients had routine
coronary arteriography using the Judkins approach. The right
femoral artery was used to introduce 7F left and right coro-
nary catheters via an 8F arterial sheath placed in the femoral
artery. In five patients, a Gensini catheter was introduced
into the left ventricular cavity from the left femoral artery.
A micromanometer-tipped catheter (Millar Mikro-tip, Mil-
lar Laboratories) was introduced through this catheter with
the tip positioned just distal to the tip of the Gensini catheter.
In four other patients, a Swan-Ganz pulmonary artery cath-
eter was introduced through the right femoral vein to mea-
sure pulmonary capillary wedge pressure . In only one pa-
tient, neither left ventricular end-di astolic nor pulmonary
capillary wedge pressure was measured during the study .
Aortic pressure was measured in all 10 patients. All pres-
sures were recorded on a commercially available recorder
(Electronics for Medicine , model VR-12) using fluid-filled
transducers (Gould P-50, Gould Inc. ). Pressures were re-
corded before, during and after each coronary injection until
they returned to baseline values .
Electrocardiographic measurements. Seven standard
electrocardiographic leads were recorded (I , II, III, aVR ,
aVL, aVF and V5)' Other precordial leads were not used
because echocardiographic images were obtained from
acoustic windows in the parasternal region. Electrocardio-
graphic recordings were obtained on a three-channel re-
corder (Hewlett Packard Corporation , model 1515B). Re-
Methods
as a result of both a brief interruption in coronary blood
flow and hyperosmolality of available contrast agents (11-16).
Nevertheless, coronary arteriography is routinely employed
for the diagnosis of coronary artery disease. The aim of the
present study was to study the safety of myocardial contrast
echocardiography in humans with normal coronary arteries,
and to compare the hemodynamic and electrocardiographic
effects of sonicated Renografin-Zo used for myocardial con-
trast echocardiography with those of nonsonicated Reno-
grafin-76 used for routine coronary arteriography.
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ing a commercially available sonicator system (Heat Sys-
tems Ultrasonics, model W-375) (19). Five milliliters of
Renografin-76 was sonicated at 20,000 cycles/s for 20 to
30 seconds at an energy output of 75 watts.
Protocol. After diagnostic catheterization, time was al-
lowed for stabilization of hemodynamic variables. The left
coronary artery was then injected with 8 to 10 ml of Ren-
ografin-76 for a left coronary angiogram. Electrocardio-
graphic and hemodynamic data were obtained before, during
and after this injection. Five minutes later, 2 to 3 ml of
sonicated contrast agent was injected into the left coronary
artery, and electrocardiographic, hemodynamic and echo-
cardiographic data obtained before, during and after injec-
tion of the agent. In five patients, myocardial contrast
echocardiography was repeated with hemodynamic and
electrocardiographic monitoring. In 7 of the 10 patients, the
right coronary artery was injected with 5 to 8 ml of Ren-
ografin-76 for a right coronary arteriogram, and electrocar-
diographic and hemodynamic data were recorded before,
during and after the injection. Five minutes later, 2 to 3 ml
of sonicated contrast agent was injected, and hemodynamic,
electrocardiographic and echocardiographic data were re-
corded.
Statistical analysis. Data were analyzed using RS/ 1(Bolt,
Beraneck, and Newman, 1983) on a VAX 111780 mini-
computer (Digital Equipment Corporation). Comparisons of
baseline data with data obtained during coronary arteriog-
raphy and myocardial contrast echocardiography were made
using Neuman-Keul's multiple comparison test whenever a
significant (p < 0.05) difference was detected by the F test
embodied in the analysis of variance (MULTICOMPARE).
Results
Seventeen injections of Renografin-76 were performed
for routine coronary arteriography, and 24 injections of son-
icated Renografin-76 were performed for myocardial con-
trast echocardiography.
Symptoms. Eight patients reported either no symptoms
or vague substernal sensations that were less marked during
myocardial contrast echocardiography than during coronary
arteriography. One patient reported, during myocardial con-
trast echocardiography, chest tightness not previously noted
during coronary arteriography; it resolved before the dis-
appearance of contrast from the myocardium. Another pa-
tient reported, after completion of the experimental proto-
col, chest tightness that responded to sublingual nitroglycerin.
No chest pain was reported in the next 24 hours by any
patient. No neurologic or visual symptoms were reported
or noted either during or after the study.
Electrocardiographic changes. Table I depicts the
electrocardiographic changes during routine coronary arte-
riography and myocardial contrast echocardiography. There
was no significant difference in the heart rate, PR interval
and QRS duration between the baseline study and myo-
cardial contrast echocardiography. In contrast, significant
bradycardia and prolongation of the PR interval and QRS
duration occurred during routine coronary arteriography.
Table 1. Electrocardiographic Changes During Intracoronary Injections of Nonsonicated and Sonicated Renografin-76 in 10 Patients
Sonicated Overall
Variable Baseline Renografin-76 Renografin-76 p Value*
Heart rate 731± 14 58
1±1
9 65 ±rlO 0.02
(beats/min) <0.05 <0.05
I NS I
QRS axis 48/± 52 511±152 52 ±141 0.001
(degrees) <0.01 NS
I <0.01 I
PR interval 17l1± 10 1821± 110 176 ±IIO 0.001(ms) <0.01 <0.01
I NS I
QRS duration 781± 10 911±12O 81 ± /10 0.001
(ms) <0.01 <0.01
I NS I
QT interval 4241± 30 540I± 170 480 ±14O 0.001
(ms) <0.01 <0.01
I p < 0.01 I
ST depression 40 70 47 0.20
(% patients)
T wave inversion 10 82 82 0.001
(% patients) I <0.01 11 NS I
I I<0.01
PVCs 10 24 6 0.30
(% patients)
*Assessed using analysis of variance. NS = not significant; PVCs = premature ventricular complexes.
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Table 2. Electrocardiographic Changes During Repeat
Intracoronary Injection of Sonicated Renografin-76 in
Five Patients
Variable Injection I Injection 2 p Value
Heart rate 60 ± 3 58 ± 4 NS
(beats/min)
QRS axis 40 ± 48 40 ± 48 NS
(degrees)
PR interval 180 ± 40 180 ± 40 NS
(ms)
QRS duration 840 ± 10 840 ± 10 NS
(ms)
QT interval 480 ± 50 450 ± 50 NS
(ms)
ST depression 40 20 NS
(% patients)
T wave inversion 60 60 NS
(% patients)
PVCs 20 20 NS
(% patients)
NS = not significant; PVCs = premature ventricular complexes.
The QT interval was significantly longer during routine
coronary arteriography than during myocardial contrast
echocardiography. The shift in QRS axis and the incidence
of transient T wave inversion were similar in the two studies.
The incidence of premature ventricular beats and ST seg-
ment depression was similar during baseline study, myo-
cardial contrast echocardiography and coronary arteriog-
raphy.
Arrhythmias were noted in two patients during coronary
arteriography and myocardial contrast echocardiography .
One patient developed transient sinus arrest with a junctional
escape rhythm (19 seconds during coronary arteriography
and 13 seconds during myocardial contrast echocardiog-
raphy) requiring intravenous atropine . The other patient de-
veloped transient (3 seconds) second and third degree block
during an inadvertent rapid injection of 5 ml of sonicated
Renografin-76 in the right coronary artery requiring intra-
venous atropine. Electrocardiographic changes were most
marked at 3 to 10 seconds after injection of Renografin-76
(nonsonicated or sonicated) and abated by 10 to 90 seconds.
Electrocardiographic changes produced by repeat injec-
tion of the same amount of sonicated Renografin-76 in the
same vessel in five patients were nearly identical (Table 2).
Hemodynamic changes. Effects of nonsonicated and
sonicated Renografin-76 on aortic systolic pressure , left ven-
tricular end-diastolic or pulmonary capillary wedge pressure
and first derivative of the change in left ventricular pressure
(dP/dt) in the nine patients in whom these measurements
were recorded are depicted in Table 3. Although the aortic
systolic pressure decreased significantly during both coro-
nary arteriography and myocardial contrast echocardiog-
raphy, the decrease was significantly greater with the for-
mer. Similar changes were noted in aortic diastolic and mean
pressures ( - 23 ± 11 versus - 9 ± 7% and - 27 ± 5
versus - 13 ± 5%, respectively) . The left ventricular end-
diastolic pressure and pulmonary capillary wedge pressure
increased significantly during coronary arteriography and
myocardial contrast echocardiography compared with base-
line. Although the percent increase was larger during the
former , this difference was not significant. Similarly, al-
though the increase in left ventricular end-diastolic pressure
and pulmonary capillary wedge pressure lasted longer dur-
ing coronary arteriography than during myocardial contrast
echocardiography (24 ± 21 versus 14 ± 7 seconds) , the
difference was not significant. In the five patients in whom
left ventricular dP/dt was measured, a significant decrease
was noted during coronary arteriography, but not during
myocardialcontrast echocardiography. The duration of change
in left ventricular dP/dt was similar during coronary arte-
riography and myocardial contra st echocardiography (20 ±
18 versus 17 ± 14 seconds).
Table 3. Hemodynamic Changes Noted During Intracoronary Injection of Nonsonicated and Sonicated Renografin-76 in
Nine Patients
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(mm Hg) (n = 9)
LV dP/dt
(n = 5)
*Assessed using analysis of variance. ASP = aortic systolic pressure; LV dP/dt = left ventricular dP/dt; LVEDP = left ventricular end-diastolic
pressure; NS = not significant; PCWP = pulmonary capillary wedge pressure.
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Figure 2. Hemodynamic variables at baseline study
and during myocardial contrast echocardiography and
coronaryarteriographyin 10subjects withnormal coro-
nary arteries. COR. INJ. = coronaryinjection;dp/dt =
first derivative of the change in left ventricular pres-
sure; LVEDP = left ventricular end-diastolic pressure;
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The effects of nonsonicated and sonicated Renografin-
76 on aortic systolic pres sure, left ventricular end-diastolic
pressure or pulmonary capillary wedge pressure and left
ventricular dP/dt were not significantly different between
left and right coronary injections (Fig. 2). However, during
left coronary injections, changes in aortic systolic pressure
and left ventricular end-diastolic pressure or pulmonary cap-
illary wedge pressure were significantly greater during coro-
nary arteriography than during myocardial contrast echo-
cardiography; changes in left ventricular dP/dt were similar.
During right coronary injections, only changes in aortic
systolic pressure were significantly greater during coronary
arteriography than during myocardial contrast echocardi-
ography.
Figure 3 illustrates the changes in aortic systolic pressure,
left ventricular end-diastolic pressure and left ventricular
dP/dt during a repeat injection of sonicated contrast agent
in five patients. The hemodynamic variables and percent
change in variables were almost identical. The duration of
changes in left ventricular end-diastolic pressure and dP/dt
was also similar (9 ± 3 versus 12 ± 2 seconds and 10 ±
3 versus 12 ± 8 seconds , respectively).
Echocardiographic changes. All echocardiograms were
reviewed for myocardial opacification and wall motion
changes durin g injection of sonicated Renografin-76. Myo-
cardial opacification of left and right coronary vascular beds
was optimal with injection of 2 to 3 cc of contrast agent s.
A " blooming" effect was noted when 5 cc of sonicated
Renografin-76 was inadvertently injected into the right coro-
nary artery of one patient. No significant wall motion ab-
normalities were noted after injection of sonicated Reno-
grafin-76. Wall motion was analyzed visually, and quantitative
methods were not used.
Discussion
The present study demonstrate s that selective intracor-
onary injections of sonicated Renografin-76 in amounts nec-
essary to produce adequ ate and reproducible myocardial
contra st enhancement during two-dimensional echocardi-
ography appear to be safe in humans. The electrocardio-
graphic and hemodynamic effects of injecting 2 ml of son-
icated Renografin-76 (which is adequate to produce opt imal
myocardial opacificat ion) are less than those associated with
injecting 5 to 10 ml of nonsonicated Renografin-76 (which
is required for a single injection during routine coronary
arteriograph y). Although these result s are based on a small
number of patients with normal coronary arteries, our data
sugges t that myocardial contrast echocardiography may be
safely used in patient s undergoing rout ine coronary arteri-
ography .
Electrocardiographic and hemodynamic effects of
contrast agents. Transient but significant electrocardio-
graphic and hemod ynam ic changes documented previously
with iodinated contrast agents are probably related in part
to transient ischemia of the sinoatrial node and myocardial
cells , and in part to the viscos ity, hypertonicity and calcium-
chelating properties of iodinated contrast agents (11- 16) .
Myocardial contrast echocardiograph y requires that micro-
bubble s of air be produ ced in agent s that are injected into
the coronary vessels . It is therefore possible that add ition
lACC Vol. 8. No.5
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Figure 3. Hemodynamic variables during repeat injection of son-
icated Renografin-76 in the left main coronary artery in five sub-
jects with normal coronary arteries. Left ventricular dP/dt is de-
picted as percent change from baseline. Abbreviations as in
Figure 2.
of such microbubbles may worsen the electrocardiographic
and hemodynamic changes noted with these agents.
Previous studies using hand agitation to produce micro-
bubbles have suggested that the microbubbles are predom-
inantly responsible for the adverse effects on coronary blood
flow and left ventricular function (20,21). Microbubbles
produced by hand agitation are usually large (12 ± 7 JL in
diameter) (9,19) and may become entrapped in the micro-
circulation, resulting in myocardial ischemia (22). When
these agents are injected into the coronary circulation, the
myocardial contrast effect noted on echocardiography usu-
ally lasts for 45 to 90 seconds (9). In contrast, sonication
produces smaller microbubb1es (5 ± 3 JL in diameter) (19),
which do not become entrapped in the microcirculation (22).
When these agents are injected into the coronary circulation,
the myocardial contrast effect noted on echocardiography
is shorter (15 to 20 seconds), implying faster coronary transit
time. In a preliminary report, Lang et al. (10) injected son-
icated and nonsonicated contrast agents into the coronary
circulation of dogs and demonstrated that the effects of equal
amounts of these agents on left ventricular function were
similar. These data suggest that sonication produces smaller
bubbles than hand agitation and that the bubbles do not
produce adverse effects on left ventricular function in ad-
dition to those produced by the contrast agent itself.
The aim of our study was not to compare sonicated versus
nonsonicated Renografin-76, but to compare the effects of
the two techniques on left ventricular function. Two milli-
liters of sonicated Renografin required for adequate contrast
enhancement of the myocardium during echocardiography
was found to be safer than 5 to 10 ml of nonsonicated
Renografin required for opacification of epicardial coronary
arteries during routine coronary arteriography. However,
the margin of safety may be narrower with sonicated versus
nonsonicated contrast agents, as exemplified in the one pa-
tient in whom 5 ml of sonicated Renografin was inadvertently
injected into the coronary circulation, producing transient
complete heart block. Furthermore, these data are derived
from patients with normal coronary arteries. Whether son-
icated Renografin is safe in patients with reduced coronary
blood flow has yet to be demonstrated. Since completion
of this study, we have injected sonicated Renografin before
and after coronary angioplasty with no adverse effects in
15 patients with coronary artery disease. However, this tech-
nique must be used in a larger number of patients and in
different clinical situations before its safety can be clearly
established. Our results suggest that it is probably safe to
use sonicated Renografin-76 in humans undergoing routine
coronary arteriography. Special emphasis, however, must
be placed on the technique of microbubble production.
Using noniodinated contrast agents. Santoso et al. (23)
recently reported that intracoronary injection of hand-agi-
tated polygelin colloid solution is safe in humans. Interest-
ingly, although they injected 5 ml of this substance into the
coronary circulation, they did not observe any change in
heart rate, systolic blood pressure or M-mode echocardio-
graphic indexes of left ventricular contractility. The inves-
tigators attribute the lack of such changes to the chemical
composition of the polygelin colloid solution which, unlike
Renografin-76, is not hyperosmolar and does not have cal-
cium-chelating properties. These data are somewhat sur-
prising. First, injection of 5 ml of a nonoxygen-carrying
substance into the coronary circulation should definitely in-
terrupt coronary blood flow and, thus, produce hemody-
namic changes. Second, as demonstrated by Levine et al.
(21), hand agitation of even an oxygen-carrying medium
such as fluosol produces effects on left ventricular function,
probably as a result of microcapillary blockage produced
by the large-sized microbubbles. We did not attempt to use
noniodinated contrast agents, because they are expensive
and not readily available. However, because they produce
fewer hemodynamic effects, sonicated noniodinated con-
trast agents may be safer in patients with poor left ventricular
function (24).
Limitation of the study. We did not quantitate regional
myocardial function using two-dimensional echocardiog-
raphy; echocardiographic images were acquired only during
injection of the sonicated contrast agent. Although we did
not see any significant changes in regional wall motion
during injection of sonicated contrast agent, it is possible
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Conclusion. Ours is the first study demonstrating the
safety of sonicated Renografin-76 in humans. The technique
is at least as safe as routine coronary arteriography in sub-
jects with normal coronary arteries. Although we have used
this technique without any side effects in an additional 15
patients undergoing coronary angioplasty, it must be used
in a larger number of patients with coronary artery disease
before its safety as a routine adjunct to coronary arteriog-
raphy can be clearly established. Our results, however, should
provide an impetus to the use of this technique in humans.
Apart from delineating perfusion zones of coronary vessels
during acute myocardial infarction and before and after coro-
nary angioplasty, this technique may be useful for measuring
absolute regional myocardial blood flow and coronary vas-
cular reserve.
We are grateful to Debra Peters for secretarial assistance and to Craig
Harding for preparing the artwork.
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